Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT06624085
- Locations
- 🇺🇸
University of California Los Angeles (UCLA) - Cancer Care - Santa Monica, Santa Monica, California, United States
🇺🇸Walter Reed National Military Medical Center, Bethesda, Maryland, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 150
- Registration Number
- NCT06624059
- Locations
- 🇦🇺
Royal North Shore Hospital, St. Leonards, New South Wales, Australia
🇦🇺Calvary Mater Newcastle, Waratah, New South Wales, Australia
🇨🇳Xiangya Hospital of Centre-South University, Changsha, China
A Study to Assess the Efficacy and Safety of RO7790121 for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
- Conditions
- Moderately to Severely Active Ulcerative Colitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 400
- Registration Number
- NCT06589986
- Locations
- 🇨🇱
Medwal, Santiago, Chile
🇧🇪AZ Delta (Campus Rumbeke), Roeselare, Belgium
🇧🇪Vitaz, Sint Niklaas, Belgium
A Study to Assess the Efficacy and Safety of Induction Therapy With RO7790121 in Participants With Moderately to Severely Active Ulcerative Colitis
- Conditions
- Moderately to Severely Active Ulcerative Colitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 350
- Registration Number
- NCT06588855
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu City, China
🇵🇱MZ Badania Slowik Zymla Sp.j., Knurów, Poland
🇭🇷Borzan Polyclinic, Osijek, Croatia
A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors
- First Posted Date
- 2024-08-05
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 180
- Registration Number
- NCT06537310
- Locations
- 🇦🇺
Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia
🇦🇺Austin Health, Heidelberg, Victoria, Australia
🇧🇪UZ Leuven Gasthuisberg, Leuven, Belgium
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC)
- Conditions
- Muscle Invasive Urothelial Carcinoma
- Interventions
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 362
- Registration Number
- NCT06534983
- Locations
- 🇺🇸
Highlands Oncology Group., Springdale, Arkansas, United States
🇺🇸City of Hope Cancer Center, Duarte, California, United States
🇺🇸Kaiser Permanente - Riverside, Riverside, California, United States
A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization
- Conditions
- Unresectable Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 113
- Registration Number
- NCT06503250
- Locations
- 🇨🇳
The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
🇨🇳The First Affiliated Hospital of Sun Yat-sen University, Guangzhou City, China
🇨🇳Zhongshan Hospital Fudan University, Shanghai, China
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung CancerKRAS G12C Lung Cancer
- Interventions
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 320
- Registration Number
- NCT06497556
- Locations
- 🇳🇱
Amphia Ziekenhuis, Breda, Netherlands
🇵🇱Dolno?L?Skie Centrum Onkologii, Pulmonologii I Hematologii, Wroc?aw, Poland
🇵🇹Hospital de Braga, Braga, Portugal
A Study Evaluating Single-agent Inavolisib and Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT06496568
- Locations
- 🇺🇸
Moores Cancer Center at UC San Diego Health, La Jolla, California, United States
🇺🇸California Cancer Associates for Research & Excellence, Inc., San Marcos, California, United States
🇺🇸Vanderbilt-Ingram Cancer Ctr, Nashville, Tennessee, United States
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
- First Posted Date
- 2024-06-10
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT06450639
- Locations
- 🇵🇱
Instytut Centrum Zdrowia Matki Polki, Lódz, Poland
🇵🇱Uniwersytecki Szpital Kliniczny w Poznaniu, Poznan, Poland
🇵🇱Uniwersyteckie Centrum Kliniczne, Gdansk, Poland